Market Place
Sourcing Support
All News #Library
Biotech
Fate Therapeutics Announces Data Presentation of FT819
30 Apr 2026 //
GLOBENEWSWIRE
Fate Therapeutics Joins Q2 2026 Conferences
09 Apr 2026 //
GLOBENEWSWIRE
Fate Pharma Discloses Employee Awards Per Nasdaq LR 5635(C)(4)
04 Mar 2026 //
GLOBENEWSWIRE
Fate Pharma Discloses Employee Awards Per Nasdaq LR 5635(C)(4)
05 Jan 2026 //
GLOBENEWSWIRE
Fate Therapeutics to Present at Piper Sandler Healthcare
25 Nov 2025 //
GLOBENEWSWIRE
Fate Pharma Shows FT819 CAR T-Cell Therapy Benefits In Lupus
26 Oct 2025 //
GLOBENEWSWIRE
Fate Pharma Discloses Employee Awards Per Nasdaq LR 5635(C)(4)
02 Oct 2025 //
GLOBENEWSWIRE
Fate Therapeutics Q2 2025 Financial Results and Updates
12 Aug 2025 //
GLOBENEWSWIRE
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 CA
28 May 2025 //
GLOBENEWSWIRE
Fate Therapeutics Receives RMAT Designation from FDA for FT819
14 Apr 2025 //
GLOBENEWSWIRE
Fate Therapeutics Reports Q4 and Full Year 2024 Financial Results
05 Mar 2025 //
GLOBENEWSWIRE
Fate Reports Employee Inducement Awards Under Nasdaq LR 5635(c)(4)
03 Jan 2025 //
GLOBENEWSWIRE
Fate Therapeutics Highlights FT522 Off-the-Shelf CAR NK Cell at ACR
18 Nov 2024 //
GLOBENEWSWIRE
Fate Presents 6-Month Follow-Up Data in Autoimmunity Study
18 Nov 2024 //
GLOBENEWSWIRE
Fate Therapeutics Highlights FT825 CAR T-cell Data at SITC 2024
09 Nov 2024 //
GLOBENEWSWIRE
Fate Therapeutics Preclinical Data on FT836 CAR T at SITC Meeting
08 Nov 2024 //
GLOBENEWSWIRE
Fate Therapeutics Reports Inducement Grant Nasdaq LR5635(c)(4)
04 Nov 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.